{
    "nctId": "NCT02687724",
    "officialTitle": "GLM Dose Optimisation to Adequate Levels to Achieve Response in Colitis (GOAL-ARC). A Nationwide Multi-centred Randomised Controlled Trial (RCT) Investigating the Use of GLM Dose Adjustment in Ulcerative Colitis (UC).",
    "inclusionCriteria": "* Patients \u2265 18 years of age\n* Subjects must be able and willing to give written informed consent and to comply with the requirements of this study protocol\n* Established diagnosis of UC and moderate-to-severe disease activity, defined as a Mayo score of 6-12, with an endoscopic subscore \u22652.\n* Patients had an inadequate response to, or had failed to tolerate, 1 or more of the following conventional therapies: oral 5-aminosalicylates, oral corticosteroids, azathioprine (AZA), and/or 6-mercaptopurine (6MP); or corticosteroid dependent (ie, an inability to taper corticosteroids without recurrence of UC symptoms).\n* Patients concurrently treated with oral 5-aminosalicylates or corticosteroids were to receive a stable dose for at least 2 weeks before baseline, and patients receiving AZA and/or 6MP were to receive a stable dose for at least 4 weeks before baseline. Patients were required to maintain stable doses of their concomitant UC medications during the study.\n* Female subjects of child bearing potential must be willing to ensure that they or their partner use effective contraception during the study and for 6 months thereafter OR\n* Surgical sterilized female patients with documentation of prior hysterectomy, tubal ligation or complete bilateral oophorectomy OR\n* Postmenopausal women with postmenopausal defined as permanent cessation \\>1 year of previously occurring menses.\n* Female subjects' serum pregnancy test performed at the screening visit and urine pregnancy test performed at the baseline visit must be negative.\n* Subjects have following investigations within 1 month prior to enrolment.\n* Routine bloods including U\\&E, FBC, LFTs, inflammatory markers (CRP) and albumin will be measured.\n* Medical history, concomitant medications\n* Intradermal reaction to Tuberculin (PPD skin test) or Mycobacterium tuberculosis antigenspecific interferon-gamma release assay (IGRA)\n* TB screening: chest X-Ray unless performed in the last 6 months\n* Stool examination for enteric pathogens including Clostridium difficile\n* Inclusion/\n* Must have minimum age of 18 Years",
    "exclusionCriteria": "* Informed consent\n* Mayo score (including sigmoidoscopy unless performed in previous 3 months)\n* Patient's weight and height and abdominal circumference\n\nExclusion Criteria:\n\n* Female subjects who are pregnant or breast-feeding or considering becoming pregnant during the study\n* Patients aged \\<18 years of age\n* Patients who cannot give informed consent,\n* Pregnant patients or those who are breastfeeding will be deemed ineligible.\n* Prior treatment with any anti-TNF agent\n* Contra-indication to use of GLM (Hypersensitivity to the active substance or to any of the excipients; Active tuberculosis (TB), acute or chronic Hepatitis B infection or other severe infections such as sepsis and/or opportunistic infections including HIV infection; Moderate or severe heart failure (NYHA class III/IV)\n* Have symptoms or signs suggestive of current active or latent TB upon medical history, physical examination and/or chest radiograph, or positive Mycobacterium tuberculosis antigen-specific interferon-gamma release assay (IGRA)\n* Patients with a history of, or at imminent risk for, colectomy; who required gastrointestinal surgery within 2 months before screening;\n* History of colonic mucosal dysplasia or adenomatous colonic polyps that were not removed\n* Screening stool study positive for enteric pathogens or Clostridium difficile toxin.\n* Oral corticosteroids at a dose \\>40 mg prednisone or its equivalent per day; receipt of cyclosporine, tacrolimus, sirolimus, or mycophenolate mofetil within 8 weeks before the first study agent injection; or use of an investigational agent within 5 half-lives of that agent before the first study agent injection.\n* Patients in recent receipt of live vaccinations within 4 weeks prior to enrolment"
}